Generated by AI
Immunocore Holdings plc ADR is a commercial-stage biotechnology company focused on developing T cell receptor-based immunotherapies designed to help the immune system recognize and eliminate diseased cells. Immunocore’s lead marketed product, KIMMTRAK, is used to treat unresectable or metastatic uveal melanoma, while its broader platform supports research and development across oncology, infectious diseases, and autoimmune disorders. The company’s ImmTAX technology underpins a portfolio of current and investigational therapies aimed at harnessing or redirecting immune responses with precision. Immunocore serves patients and healthcare providers through specialized therapies that address serious, hard-to-treat conditions, and its programs span clinical development as well as commercial operations in key international markets. Headquartered in Abingdon, United Kingdom, Immunocore Holdings plc ADR remains a notable participant in the biotechnology sector through its focus on novel immune-based medicines.
Website92 Park Drive
Abingdon, OX14 4RY
United Kingdom
The latest articles about IMCR.
2026-11-10. The following slide deck was published by Immunocore Holdings plc in conjunction with this event.
(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November. UBS Global Biopharma Conference 2026Fireside Chat: Tues
Summary of May 31's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Sep 9's posts. Generated by AI.
Investors talking about IMCR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.